Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

46 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
The mammalian target of the rapamycin (mTOR) kinase pathway: its role in tumourigenesis and targeted antitumour therapy.
Janus A, Robak T, Smolewski P. Janus A, et al. Cell Mol Biol Lett. 2005;10(3):479-98. Cell Mol Biol Lett. 2005. PMID: 16217558 Review.
Rapamycin, the mTOR kinase inhibitor, sensitizes acute myeloid leukemia cells, HL-60 cells, to the cytotoxic effect of arabinozide cytarabine.
Janus A, Linke A, Cebula B, Robak T, Smolewski P. Janus A, et al. Anticancer Drugs. 2009 Sep;20(8):693-701. doi: 10.1097/CAD.0b013e32832e89b4. Anticancer Drugs. 2009. PMID: 19584709
Multi-drug transporter MDR1 gene polymorphism and prognosis in adult acute lymphoblastic leukemia.
Jamroziak K, Balcerczak E, Cebula B, Kowalczyk M, Panczyk M, Janus A, Smolewski P, Mirowski M, Robak T. Jamroziak K, et al. Among authors: janus a. Pharmacol Rep. 2005 Nov-Dec;57(6):882-8. Pharmacol Rep. 2005. PMID: 16382213
Cladribine combined with cyclophosphamide and mitoxantrone is an active salvage therapy in advanced non-Hodgkin's lymphoma.
Robak T, Lech-Maranda E, Janus A, Blonski J, Wierzbowska A, Gora-Tybor J. Robak T, et al. Among authors: janus a. Leuk Lymphoma. 2007 Jun;48(6):1092-101. doi: 10.1080/10428190701361216. Leuk Lymphoma. 2007. PMID: 17577772 Clinical Trial.
No influence of 3435C>T ABCB1 (MDR1) gene polymorphism on risk of adult acute myeloid leukemia and P-glycoprotein expression in blast cells.
Jamroziak K, Balcerczak E, Cebula B, Janus A, Mirowski M, Robak T. Jamroziak K, et al. Among authors: janus a. Ther Drug Monit. 2006 Oct;28(5):707-11. doi: 10.1097/01.ftd.0000245770.75097.3f. Ther Drug Monit. 2006. PMID: 17038891
Toward personalized therapy for chronic lymphocytic leukemia: DSC and cDNA microarray assessment of two cases.
Rogalińska M, Franiak-Pietryga I, Błoński JZ, Góralski P, Maciejewski H, Janus A, Robak P, Mirowski M, Piekarski H, Robak T, Kiliańska ZM. Rogalińska M, et al. Among authors: janus a. Cancer Biol Ther. 2013 Jan;14(1):6-12. doi: 10.4161/cbt.22623. Epub 2012 Oct 31. Cancer Biol Ther. 2013. PMID: 23114648 Free PMC article.
Changes in the apoptotic gene expression profile in CLL patients treated with rituximab combined with cladribine and cyclophosphamide-preliminary results.
Franiak-Pietryga I, Maciejewski H, Wolowiec D, Salagacka A, Blonski JZ, Janus A, Kotkowska A, Wawrzyniak E, Ghia P, Mirowski M, Robak T, Korycka-Wolowiec A. Franiak-Pietryga I, et al. Among authors: janus a. Leuk Res. 2012 Sep;36(9):1134-40. doi: 10.1016/j.leukres.2012.04.026. Epub 2012 May 18. Leuk Res. 2012. PMID: 22608309 Clinical Trial.
Long-lasting extreme anemia during the therapy of acute lymphoblastic leukemia in a Jehovah's Witness patient.
Chojnowski K, Janus A, Bliźniewska K, Robak M, Treliński J. Chojnowski K, et al. Among authors: janus a. Transfusion. 2016 Oct;56(10):2438-2442. doi: 10.1111/trf.13703. Epub 2016 Jul 7. Transfusion. 2016. PMID: 27385671
Moxetumomab pasudotox for the treatment of hairy cell leukemia.
Janus A, Robak T. Janus A, et al. Expert Opin Biol Ther. 2019 Jun;19(6):501-508. doi: 10.1080/14712598.2019.1614558. Epub 2019 May 10. Expert Opin Biol Ther. 2019. PMID: 31045462 Review.
The functional in vitro response to CD40 ligation reflects a different clinical outcome in patients with chronic lymphocytic leukemia.
Scielzo C, Apollonio B, Scarfò L, Janus A, Muzio M, Ten Hacken E, Ghia P, Caligaris-Cappio F. Scielzo C, et al. Among authors: janus a. Leukemia. 2011 Nov;25(11):1760-7. doi: 10.1038/leu.2011.149. Epub 2011 Jun 28. Leukemia. 2011. PMID: 21709686
46 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback